retatrutide phase 2 trial ESC 2024: improves lipid and cardiovascular risk profile in II Retatrutide Dosing Schedule: Proven 2026

You can call us today to get customised diet plans, along with professional GLP-1 prescriptions

If this applies to you, start lighter than you think you need to

however, their administration is frequently accompanied by adverse events, predominantly gastrointestinal.218,219 Specifically, GLP-1RAs have been strongly linked to gastrointestinal symptoms, such as nausea, vomiting, and diarrhea, with incidence rates influenced by dosage and concomitant therapies.78 Moreover, the use of GLP-1RAs may be associated with an elevated risk of pancreatitis and thyroid-related disorders, although these associations have not been definitively established.220 Analysis of data from the US Food and Drug Administration Adverse Event Reporting System revealed that GLP-1RAs, particularly semaglutide and exenatide, are significantly correlated with gastrointestinal adverse events, including nausea, vomiting, delayed gastric emptying, and pancreatitis.221 Dual receptor agonists targeting GLP-1 and GIP, such as tirzepatide, have also exhibited promising efficacy in diabetes management, notably in terms of weight reduction and glycemic control

Acid reflux moves stomach acids back up to the esophagus and sometimes into the mouth, which can result in sour, smelly breath that seems to linger

Higher drug levels mean stronger insulin secretion in response to meals, which could theoretically cause hypoglycemia

This is the first time the GIP/GLP-1 advantage over GLP-1 alone has been proven in a direct comparison, and it is why I treat "tirzepatide beats semaglutide" as a settled question rather than an open debate